Roche (OTCMKTS:RHHBY - Get Free Report) was upgraded by equities researchers at Sanford C. Bernstein to a "strong-buy" rating in a research note issued on Thursday,Zacks.com reports.
Roche Stock Performance
RHHBY opened at $39.25 on Thursday. Roche has a twelve month low of $29.20 and a twelve month high of $42.43. The business's 50 day moving average is $36.14 and its 200-day moving average is $38.25. The company has a quick ratio of 0.97, a current ratio of 1.26 and a debt-to-equity ratio of 0.86.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Bard Financial Services Inc. grew its position in Roche by 37.7% in the fourth quarter. Bard Financial Services Inc. now owns 110,850 shares of the company's stock worth $3,866,000 after buying an additional 30,350 shares during the last quarter. GAMMA Investing LLC increased its holdings in Roche by 57.7% in the third quarter. GAMMA Investing LLC now owns 7,944 shares of the company's stock worth $317,000 after buying an additional 2,906 shares during the last quarter. Diversified Trust Co raised its holdings in shares of Roche by 6.4% during the 3rd quarter. Diversified Trust Co now owns 59,742 shares of the company's stock valued at $2,396,000 after purchasing an additional 3,613 shares in the last quarter. Canopy Partners LLC raised its stake in shares of Roche by 4.6% in the 3rd quarter. Canopy Partners LLC now owns 7,772 shares of the company's stock valued at $310,000 after acquiring an additional 344 shares in the last quarter. Finally, Verity Asset Management Inc. acquired a new position in Roche in the 3rd quarter valued at $253,000.
Roche Company Profile
(
Get Free Report)
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Roche, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.
While Roche currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
